PAVmed Inc. — FY2021 Form 10-K Summary
Business context and reporting period
PAVmed is a multi-product medical technology company developing and commercializing products across diagnostics, medical devices, digital health, and emerging innovations. This filing covers the fiscal year ended December 31, 2021; financial amounts below are in U.S. dollars, generally millions unless noted. The company describes 2020–2021 as infrastructure-building and transition years, with commercial expansion planned as the primary focus from 2022 onward.
EsoGuard and EsoCheck are the principal commercial focus. EsoCheck has FDA 510(k) clearance and European CE marking; EsoGuard is marketed in the U.S. as a laboratory-developed test (LDT), with FDA PMA studies in progress. CarpX also has FDA 510(k) clearance and CE marking. Other products, including EsoCure, PortIO, NextFlo, and Veris technologies, remain in development or early commercialization.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0.5 million | $0 |
| Cost of revenue | $0.585 million | $0 |
| Gross profit (loss) | $(0.085) million | $0 |
| Sales and marketing | $8.9 million | $2.8 million |
| General and administrative | $25.6 million | $9.6 million |
| Research and development | $19.8 million | $11.0 million |
| Loss from operations | $(54.4) million | $(23.4) million |
| Net loss before noncontrolling interests | $(56.1) million | $(35.9) million |
| Net loss attributable to PAVmed | $(50.3) million | $(34.3) million |
| Net loss per share attributable to common stockholders | $(0.65) | $(0.73) |
| Net cash used in operating activities | $(40.6) million | $(21.9) million |
FY2021 revenue came from Lucid’s EsoGuard commercialization agreement with ResearchDx, which began in August and provided a fixed monthly fee. Cost of revenue exceeded revenue, resulting in a negative gross margin. Revenue remains immaterial relative to operating costs; the filing does not report positive operating cash flow or profitability.
Cash was $77.3 million at December 31, 2021, versus $17.3 million a year earlier. Total current assets were $82.6 million and current liabilities $7.6 million, implying working capital of approximately $75.1 million. Total assets were $87.0 million, total liabilities $7.6 million, and consolidated stockholders’ equity $79.4 million. PAVmed reported no convertible-note balances at year-end, having repaid its prior convertible notes in the first quarter of 2021.
Cash provided by financing activities was $104.3 million in 2021, including $62.0 million of public Lucid IPO proceeds, $55.0 million from PAVmed registered offerings, and warrant and option exercises; these totals are before considering the associated offering costs and other financing outflows. Investing activities used $3.7 million, including $2.2 million for acquisitions and $1.5 million for equipment. The balance sheet and cash-flow figures are consolidated, including majority-owned subsidiaries.
Material changes versus FY2020
- Revenue rose from zero to $0.5 million, but cost of revenue was $0.585 million and the business remained substantially pre-profit.
- Operating expenses increased by approximately $31.0 million to $54.3 million, reflecting expansion of commercial, administrative, clinical, and product-development activities. Stock-based compensation rose to $15.0 million from $2.0 million and was a significant noncash expense.
- Operating cash use increased to $40.6 million from $21.9 million, while net loss attributable to PAVmed increased to $50.3 million from $34.3 million.
- Cash increased by $60.0 million, primarily because of equity financing and Lucid’s IPO. Lucid’s IPO also increased noncontrolling interests; PAVmed held approximately 80% of Lucid after the offering.
- Prior convertible debt was fully repaid in Q1 2021. FY2021 also included a $3.7 million debt-extinguishment loss, a $1.7 million noncash gain from changes in fair value of convertible debt, and $0.3 million of PPP loan forgiveness income.
Outlook, risks, contingencies, and unusual items
- Management outlook: PAVmed expects recurring operating losses and continued reliance on debt and equity financing. Management stated that cash on hand and committed financing sources were expected to fund operations for one year from issuance of the financial statements. This is not a profitability forecast.
- Commercial and regulatory milestones: Management targeted completion of EsoGuard-BE-1 and BE-2 trial enrollment around the end of 2022 or early 2023 and a PMA submission in 2023; other portions of the filing cite different target timing, so the schedule is not entirely consistent. NextFlo’s 510(k) submission was targeted for the second half of 2022; Veris design freeze was expected by year-end 2022. These are forward-looking targets, not assured outcomes.
- Reimbursement and LDT regulation: CMS set an EsoGuard Medicare payment determination of $1,938.01 effective January 1, 2021, but MolDx local coverage determination was still pending. Private-payor coverage and payment were not established broadly. The regulatory framework for LDTs remains uncertain, and the company is pursuing FDA PMA approval for EsoGuard used with EsoCheck.
- Subsequent financing: In March 2022, PAVmed agreed to issue up to $50 million principal of senior secured convertible notes. The initial $27.5 million principal closing yielded $24.9 million cash proceeds on April 5, 2022 after lender fees. The notes bear 7.875% interest, have a $5.00 fixed conversion price and a 24-month maturity, with installment repayment provisions, covenants, and potential dilution. Additional closings are conditional. Lucid separately entered a committed equity facility of up to $50 million, subject to its terms.
- Subsequent operating commitments: Lucid acquired laboratory assets from ResearchDx for up to $6.2 million and entered a three-year management services agreement with approximately $1.8 million in quarterly payments. These post-year-end arrangements are not reflected in December 31, 2021 balance-sheet amounts.
- Litigation: A stockholder litigation settlement concerning the 2020 annual meeting was pending court approval. Benchmark-related claims were refiled in New York in February 2022 after dismissal of the prior federal case; PAVmed disputes the allegations and intends to contest them.
- Other risks: The company has a limited operating history, minimal revenue, significant cash needs, commercialization and clinical-trial execution risk, dependence on third-party manufacturing and laboratory services, reimbursement uncertainty, competition, and potential dilution. COVID-19 could affect healthcare access, trials, supply chains, and commercialization.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2021. The auditor issued an unqualified opinion on the financial statements but did not attest to internal controls. The audit identified valuation of Lucid shares before its IPO as a critical audit matter.
Most important facts for investors to verify
- Review the audited statements and notes for the full cash-burn profile, stock-based compensation, subsidiary noncontrolling interests, and any commitments not captured by headline cash balances.
- Track EsoGuard test volumes, realized revenue and unit economics, Medicare coverage decisions, private-payor reimbursement, and progress toward FDA PMA approval.
- Confirm the timing, availability, covenants, cash-payment requirements, and dilution implications of the March 2022 secured notes and Lucid equity facility.
- Check whether Lucid’s laboratory acquisition and recurring management-service payments improve testing capacity and costs as intended.
- Monitor trial enrollment and outcomes, product clearances, commercial adoption, litigation developments, and any changes in internal controls or financing needs.